Form 4: Beam Therapeutics SVP, Finance and Treasurer, Bethany J Cavanagh, Reports Stock Option Grant

Bethany J Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics, reports the acquisition of a stock option for 20,000 shares of common stock.

Summary

• On January 31, 2025, Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., was granted a stock option to purchase 20,000 shares of common stock.
• The exercise price of the stock option is $25.92.
• The stock option vests in equal monthly installments over 48 months, contingent upon continued service with Beam Therapeutics.
• The expiration date of the stock option is January 31, 2035.
• Following the reported transaction, Ms. Cavanagh directly owns derivative securities for 20,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard executive compensation practice. It's neither overwhelmingly positive nor negative from an investment perspective.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. These grants are typically subject to vesting schedules based on continued employment.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Beam Therapeutics.
• Comparable companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options as part of their executive compensation strategy.
• The vesting schedule of 48 months is a typical vesting period for stock options in the industry, aligning with long-term performance goals.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.
• The grant incentivizes the executive to work towards increasing shareholder value.

Key Dates